The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

#4658

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Aim(s): To review malnutrition after 5-years follow-up in a cohort of patients with GEP-NETs treated with monthly SSAs.

Materials and methods: Prospective longitudinal single-centre cohort study of patients with GEP-NET treated with SSAs. Patients were screened for malnutrition between Aug 2018–Feb 2019 (baseline). Baseline data were compared with 5-year follow-up data. Analyses included BMI, nutrition status using the malnutrition-universal-screening-tool (MUST), and vitamin-D deficiency (VDD) 25-(OH)D levels ≤50ng/mL.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,